This report compiles 23 market-moving events that could play out in January with forward-looking, investigative reporting on each.
A sampling of headlines:
• Exelixis’ Cabometyx and Merck’s Keytruda approvable in second-line HCC but market obstacles set by available therapies
• Aurinia’s Phase II voclosporin study may struggle to show superior tolerability over Allergan’s Restasis in dry eye
• SAGE’s Phase II PPD trial of SAGE-217 draws psychiatrist optimism due to brexanolone-like MOA and MDD data